Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ATXI

ATXI - Avenue Therapeutics Inc Stock Price, Fair Value and News

$0.550.00 (0.00%)
Market Closed

Price Targets

ATXI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ATXI Price Action

Last 30 days

89.7%

Last 90 days

175%

Trailing 12 Months

129.2%

ATXI RSI Chart

ATXI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ATXI Valuation

Market Cap

1.8M

Price/Earnings (Trailing)

-0.62

Price/Sales (Trailing)

1.29

Price/Free Cashflow

-0.99

ATXI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

ATXI Fundamentals

ATXI Revenue

Revenue (TTM)

1.4M

ATXI Earnings

Earnings (TTM)

-2.9M

Earnings Growth (Yr)

54.08%

Earnings Growth (Qtr)

-3.81%

ATXI Profitability

Return on Equity

-158.79%

Return on Assets

-99.25%

Free Cashflow Yield

-101.16%

ATXI Investor Care

Shares Dilution (1Y)

3.49%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250001.4M
20240000
Get all data in R, Python etc through our Historical Stock Data APIs

About Avenue Therapeutics Inc

ATXI
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.
 CEO
 WEBSITEavenuetx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES2

Avenue Therapeutics Inc Frequently Asked Questions

ATXI is the stock ticker symbol of Avenue Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Thu Apr 30 2026, market cap of Avenue Therapeutics Inc is 1.81 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Thu Apr 30 2026, ATXI's PE ratio (Price to Earnings) is -0.62 and Price to Sales (PS) ratio is 1.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATXI PE ratio will change depending on the future growth rate expectations of investors.